The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol

Medical News

Gays: Drug Study Sees Up to 92 Percent Cut in HIV Risk

July 21, 2011

Oral emtricitabine/tenofovir (FTC/TDF, branded as Truvada) taken daily to prevent HIV infection is most effective in patients who have the highest levels of the drugs in their blood, according to a late-breaking study presented Wednesday at the conclusion of the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Rome.


In November, the iPrEx study reported on the efficacy of daily FTC/TDF used as pre-exposure HIV prophylaxis (PrEP) among 2,499 sexually active, non-HIV-infected men who have sex with men (MSM), and male-to-female transgender individuals who have sex with men. Overall, PrEP reduced HIV infection risk by 43.8 percent compared to placebo (36 HIV infections/1,251 on PrEP vs. 64 infections/1,248 on placebo).

However, in the subset of participants with the highest concentrations of FTC/TDF in their blood, the risk of HIV infection was 92 percent lower compared with placebo, Dr. Robert Grant, of the Gladstone Institute of Virology and Immunology in San Francisco, and colleagues reported Wednesday.

Blood levels of FTC/TDF are tied to adherence as well as how well the drug is absorbed. Among seroconverters, lack of drug resistance or viral suppression indicated low PrEP exposure, the study authors reported.

"PrEP is an important HIV prevention tool with the potential to prevent significant numbers of new HIV infections," said Grant. "These data confirm that PrEP is safe and effective in MSM, one of the populations most affected by HIV worldwide."

Back to other news for July 2011

Adapted from:
Agence France Presse

More From This Resource Center

Undetectable Viral Load and HIV Prevention: What Do Gay and Bi Men Need to Know?

Do HIV-Negative Gay Men Need Condoms if They're on PrEP? Here's What I Tell My Patients

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
See Also
More News and Research on HIV Medications for HIV Prevention

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our advertising policy.